AzTrials
AzTrials

Gingival RecessionPhase 4NCT02486991

Tunnel With and Without Intramucosal Vertical Incisions

A Phase 4 study testing Tunnel + AlloDerm® and Tunnel + AlloDerm® + Verticals in people with Gingival Recession, run by University of Louisville.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Thirty patients will be treated: 15 with a coronally positioned tunnel technique plus intramucosal verticals with AlloDerm® (test treatment) and 15 with a coronally positioned tunnel technique alone with AlloDerm® (control treatment). Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Gingival Recession
What is being tested?
Tunnel + AlloDerm® and Tunnel + AlloDerm® + Verticals
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
No sites listed yet
Study dates
Aug 2015to Jun 2016
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • At least one Miller Class I or II mucogingival defect ≥ 3 mm (Miller 1985).
  • The mucogingival defect must be on a non-molar tooth.
  • Patients must be at least 18 years of age.

Who cannot join

  • Patients with debilitating systemic or diseases that significantly affect the periodontium.
  • Patients with a known allergy to any of the materials that will be used in the study, including systemic antibiotics (tetracycline and doxycycline).
  • Patients requiring antibiotic prophylaxis.
  • Root surface restorations at the site of recession.
  • No detectable CEJ
  • Patients who fail to maintain oral hygiene levels of at least 80% plaque free surfaces.
Show all 12Show fewer
  • Patients who are pregnant or lactating.
  • Patients who use tobacco products (smoking or smokeless tobacco).
  • Patients with alcohol abuse problems.
  • Patients undergoing long-term steroid therapy.
  • History of previous root coverage procedures, graft or GTR, on the test teeth.
  • Patients who fail to complete the informed consent form.

About this study

Official title: Impact of Intramucosal Vertical Incisions on the Coronally Positioned Tunnel Using Acellular Dermal Matrix

Thirty patients will be treated: 15 with a coronally positioned tunnel technique plus intramucosal verticals with AlloDerm® (test treatment) and 15 with a coronally positioned tunnel technique alone with AlloDerm® (control treatment). The surgical procedure for the control sites will consist of a coronally positioned tunnel preparation that is a modification of a previous tunnel technique described by Allen AL (Allen AL, 1994a/1994b). This tunnel technique was modified to include coronal positioning of the soft tissue over an allograft (E.P Allen). The surgical procedure for the test sites will consist of a coronally positioned tunnel preparation (E.P. Allen) plus the use of mesial and/or distal intramucosal verticals, a modification of the vestibular incision subperiosteal tunnel access (VISTA) approach (Zadeh H, 2011). Each patient will provide at least one Miller Class I or II facial recession defect, ≥ 3 mm. Patients will be randomly selected by a coin toss to receive either the test or control treatment. Three exams for measurements will be performed per patient on total: preoperative, at week eight and 16 (4 months) postoperatively. The primary aim is to compare the percent root coverage obtained with acellular dermal matrix using the coronally positioned tunnel technique alone or with intramucosal verticals.

Read the detailed description

Thirty patients will be treated: 15 with a coronally positioned tunnel technique plus intramucosal verticals with AlloDerm® (test treatment) and 15 with a coronally positioned tunnel technique alone with AlloDerm® (control treatment). The surgical procedure for the control sites will consist of a coronally positioned tunnel preparation that is a modification of a previous tunnel technique described by Allen AL (Allen AL, 1994a/1994b). This tunnel technique was modified to include coronal positioning of the soft tissue over an allograft (E.P Allen). The surgical procedure for the test sites will consist of a coronally positioned tunnel preparation (E.P. Allen) plus the use of mesial and/or distal intramucosal verticals, a modification of the vestibular incision subperiosteal tunnel access (VISTA) approach (Zadeh H, 2011). In both the test and control group, the AlloDerm® will be sutured using a continuous sling suture technique with a Maxon 5-0, 3/8 circle 13 mm needle and the tissue will be coronally positioned and sutured separately using a continuous sling suture technique (line angle to line angle) with PTFE 4-0, 3/8 circle 13.1 mm needle. In the test group, the intramucosal vertical incisions will be sutured using simple interrupted sutures with PTFE 4-0, 3/8 circle 13.1 mm needle. Each patient will provide at least one Miller Class I or II facial recession defect, ≥ 3 mm. Each patient will initially receive a full diagnostic work-up to include the periapical and bite-wing radiographs of the selected site and adjacent teeth, study casts, intra-oral photographs, and full mouth clinical examination. Pre-surgical preparation will include detailed oral hygiene instructions, scaling and root planing under local anesthesia, and occlusal adjustment if indicated. Baseline data on test and adjacent teeth will be recorded on the day of surgical treatment to include: Miller's classification of recession defects, Plaque Index, Gingival Index, Bleeding on Probing Index, Gingival Margin Levels (Recession), Keratinized Tissue, Clinical Attachment Level, Clinical Tooth Mobility, Creeping Attachment, Tooth Vitality, Radiographic Examination, Patient Models, and Clinical photos. Patients will be randomly selected by a coin toss to receive either the test or control treatment. Mentor will toss the coin immediately prior to beginning surgical procedure. Patients will be evaluated postoperatively for a period of 4 months. The examiner will be blinded and will not be aware of the patient treatment at any time during the term of the study. Three exams for measurements will be performed per patient on total: preoperative, at week eight and 16 (4 months) postoperatively. The primary aim is to compare the percent root coverage obtained with acellular dermal matrix using the coronally positioned tunnel technique alone or with intramucosal verticals. Means and standard deviations will be calculated for all parameters. Statistical significance of the mean residual recession data for each parameter will be analyzed using a paired t-test to detect within group statistical differences and an unpaired t-test to detect between group statistical differences. The sample size of 15 per group will afford 80% statistical power to detect a difference of 1.0 mm coverage between groups. Sample size and power calculations are based on data from previous studies.

All surgical procedures will be completed by one operator under the direction of one mentor. First, presurgical measurements will be taken. Defect width will be measured horizontally at the interproximal osseous crest level and 1.0 mm coronal to the defect base. Probing depths, width of keratinized tissue, and gingival margin levels will also be measured. Next, treatment modality will be determined and assigned to the defect. Local anesthesia will be administered, tissue elevated, and measurements of the level of the alveolar crest will be made directly in reference to the CEJ. The alveolar crest will be measured vertically from the mid-buccal, or greatest point of the defect, and proximal osseous crest levels. The soft tissue recession defect will be measured horizontally and vertically for the osseous measurements. Root surfaces will be meticulously root planed using hand instruments to obtain a smooth, hard root surface, then the incisions will be made. No osseous recontouring will be performed.

The surgical procedure for the control sites will consist of a coronally positioned tunnel preparation that is a modification of a previous tunnel technique described by Allen AL (Allen AL, 1994a/1994b). This tunnel technique was modified to include coronal positioning of the soft tissue over an allograft (E.P Allen). Split-thickness dissection beyond the mucogingival junction will be made to elevate the tissue and allow adequate coronal positioning. The tunnel is dissected using a specialized microsurgical kit. The tunnel and ADM will extend at least one tooth mesial and distal to the recession site. Papillae are completely elevated off the osseous crest so that the whole tissue complex is mobile and can be coronally positioned. In cases where access is difficult, an incision will be made to release the papilla to prevent tearing the tissue.

The surgical procedure for the test sites will consist of a coronally positioned tunnel preparation (E.P. Allen) plus the use of mesial and/or distal intramucosal verticals, a modification of the vestibular incision subperiosteal tunnel access (VISTA) approach (Zadeh H, 2011). The procedure will begin with one or multiple (mesial and distal) intramucosal vertical incisions, with the location of access depending on the sites being treated. The intramucosal incision is made through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate as well as root dehiscences. The tunnel and ADM will extend at least one tooth mesial and distal to the recession site. The tunnel is dissected using a specialized microsurgical kit. It is crucial to extend the tunnel elevation sufficiently beyond the mucogingival margin as well as through the gingival sulci of the teeth being augmented to allow for low-tension coronal repositioning of the gingiva. The tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papillae.

For both control and test groups, the Alloderm® is hydrated in two baths: first with sterile saline for a minimum of five minutes or until the backing separates from the Alloderm®, the second with sterile saline plus tetracycline at a ratio of 5 mg tetracycline / 1 mL saline until the tissue is fully hydrated. Next, the AlloDerm® will be adjusted to completely cover the defect, positioned against the root surface, at the CEJ, and the inferior and lateral borders of the grafts will extend at least 3.0 mm beyond the osseous defect margins. In the control group, the AlloDerm® will be sutured using a continuous sling suture technique with a Maxon 5-0, 3/8 circle 13 mm needle and the tissue will be coronally positioned and sutured separately using a continuous sling suture technique (line angle to line angle) with PTFE 4-0, 3/8 circle 13.1 mm needle. In the test group, the AlloDerm® will be sutured using a continuous sling suture technique with a Maxon 5-0, 3/8 circle 13 mm needle and the tissue will be coronally positioned and sutured separately using a continuous sling suture technique (line angle to line angle) with PTFE 4-0, 3/8 circle 13.1 mm needle. The intramucosal vertical incisions will be sutured using simple interrupted sutures with PTFE 4-0, 3/8 circle 13.1 mm needle.

Post-operative instructions will be given to the patients along with prescriptions, in appropriate cases, for systemic doxycycline hyclate 100 mg once a day for 14 days; an anti-inflammatory agent (naproxen 375 mg q12h for 7 days); an analgesic (Vicodin ES q6-8h prn pain); a steroid, Medrol dose pack, 21 tablets of 4 mg methylprednisolone; 6 tablets on day 1, 5 on day 2, decrease by 1/day until last tablet dose on day 6, or dexamethazone 1mg, 18 tablets, 3 tablets/day for 1st 3 days, 2/day for the next 3 days, 1/day for the last 3 days (always taken in the morning). The surgical procedures will be documented with clinical photographs.

Being tested
Tunnel + AlloDerm®, Tunnel + AlloDerm® + Verticals
Medical subject headings
Gingival Recession

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tunnel + AlloDerm®Procedure or surgery

    A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).

  • Tunnel + AlloDerm® + VerticalsProcedure or surgery

    The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).

Study groups in NCT02486991
Study groupRoleWhat they receive
Tunnel + AlloDerm®Active comparatorA coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
Receives: Procedure: Tunnel + AlloDerm®
Tunnel + AlloDerm® + VerticalsExperimentalThe use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
Receives: Procedure: Tunnel + AlloDerm®; Procedure: Tunnel + AlloDerm® + Verticals

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent root coverage

    Initial and final recession will be measured from the cementoenamel junction to the gingival margin in millimeters. Root coverage will be determined by the amount of initial recession minus the final recession. Percent root coverage will be determined by root coverage divided by initial recession, multiplied by 100.

    Measured: 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jul 2015 (estimated)
  2. Study startAug 2015
  3. Primary completionJun 2016
  4. Study completionJun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02486991
Sponsor's protocol ID
15.0532
Status last verified
Dec 2016
First submitted
19 Jun 2015
Last updated
8 Dec 2016
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Tunnel + AlloDerm® and Tunnel + AlloDerm® + Verticals in people with Gingival Recession, run by University of Louisville.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent root coverage (time frame: 4 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2016.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in